 H.C. Wainwright initiated coverage on Clene Inc NASDAQ: CLNN with a Buy rating and a 16 price target. Clene is focused on the development of novel clean-surfaced nanotechnologies consisting of transition element nanocrystals for central nervous disorders, such as. 